Last: | $ |
---|---|
Change Percent: | -2.27% |
Open: | $1.24 |
Close: | $1.29 |
High: | $1.29 |
Low: | $1.20 |
Volume: | 78,429 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $1.24 | $1.29 | $1.29 | $1.20 | 78,429 | 10-17-2019 |
$ | $1.36 | $1.32 | $1.66 | $1.25 | 883,783 | 10-16-2019 |
$ | $1.29 | $1.35 | $1.40 | $1.23 | 101,489 | 10-15-2019 |
$ | $1.30 | $1.30 | $1.35 | $1.22 | 169,150 | 10-14-2019 |
$ | $1.22 | $1.15 | $1.30 | $1.1414 | 138,300 | 10-11-2019 |
$ | $1.21 | $1.21 | $1.25 | $1.19 | 16,832 | 10-10-2019 |
$ | $1.28 | $1.22 | $1.30 | $1.10 | 70,035 | 10-09-2019 |
$ | $1.35 | $1.28 | $1.37 | $1.22 | 86,448 | 10-08-2019 |
$ | $1.40 | $1.37 | $1.45 | $1.32 | 41,235 | 10-07-2019 |
$ | $1.47 | $1.41 | $1.52 | $1.28 | 112,756 | 10-04-2019 |
$ | $1.61 | $1.45 | $1.64 | $1.41 | 82,980 | 10-03-2019 |
$ | $1.67 | $1.60 | $1.68 | $1.56 | 68,510 | 10-02-2019 |
$ | $1.66 | $1.69 | $1.75 | $1.63 | 108,141 | 10-01-2019 |
$ | $1.68 | $1.67 | $1.71 | $1.62 | 46,698 | 09-30-2019 |
$ | $1.63 | $1.68 | $1.72 | $1.62 | 31,140 | 09-27-2019 |
$ | $1.60 | $1.68 | $1.69 | $1.57 | 33,530 | 09-26-2019 |
$ | $1.61 | $1.62 | $1.68 | $1.55 | 70,361 | 09-25-2019 |
$ | $1.73 | $1.63 | $1.78 | $1.58 | 198,375 | 09-24-2019 |
$ | $1.69 | $1.70 | $1.81 | $1.57 | 114,961 | 09-23-2019 |
$ | $1.69 | $1.69 | $1.7355 | $1.57 | 68,490 | 09-20-2019 |
News, Short Squeeze, Breakout and More Instantly...
RADNOR, Pa., March 19, 2021 (GLOBE NEWSWIRE) -- NeuroRx, Inc. announced the first patient in its P2/3 study of inhaled ZYESAMI™ in the treatment of moderate and severe COVID-19 (AVICOVID-2) was dosed at the University of California Irvine. The trial will be conducted at 10-15 clinica...
GERMANTOWN, Md. , Sept. 2, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today provided the following letter from Dr. Ken Carter , the Company's Executive Chairm...
GERMANTOWN, Md. , May 27, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need, today announced the closing of its previously announced $5 million registered...